Immune Regulation Limited
Immune Regulation Limited: Immune Regulation Ltd appoints Jonathan Rigby as Chief Executive Officer
DGAP-News: Immune Regulation Limited
/ Key word(s): Personnel
Immune Regulation Ltd appoints Jonathan Rigby as Chief Executive Officer Pioneering new technologies for resetting the immune system, developing novel, first-in-class therapies for inflammatory and immunological diseases (London UK, 27 March 2020) Immune Regulation Ltd, a clinical stage biotech company, today announces the appointment of Jonathan Rigby as CEO and a member of the Board of Directors. Based in the U.S., Jonathan is an experienced CEO with three productive decades of pharmaceutical, biotech and drug delivery technology value creating achievements. In 2011 he became the CEO of SteadyMed Therapeutics Inc. and focused the company on the development of drug device combination products to treat Pulmonary Hypertension. He led the company through a Nasdaq listing in 2015 (Nasdaq: STDY) and a public-to-public company sale to United Therapeutics (Nasdaq: UTHR) in late 2018. In 2006 he cofounded Zogenix, Inc. (Nasdaq: ZGNX) a specialty pharmaceutical company now focused on the development and commercialization of drug products to treat rare diseases and was instrumental in its listing on Nasdaq in 2010. Earlier in his career, Jonathan held commercial and business development positions of increasing responsibility at large pharmaceutical companies including Merck and Bristol Myers Squibb and Profile Therapeutics, now Phillips Medical. Dr. Dominik Escher, Chairman of Immune Regulation said:
For further enquiries Immune Regulation Ltd. About Immune Regulation Existing therapies are designed to suppress the immune system and require chronic dosing to treat the inflammation, frequently causing severe side effects. Immune Regulation’s first in class immune regulating and resetting therapies have demonstrated unique efficacy and safety in pre-clinical and human studies without suppressing the immune system. These therapies exhibit short pharmacokinetic activity but reset the immune system from a pro-inflammatory to a regulatory state to induce disease remission in patients with allergic and immune mediated diseases, without the negative effects of chronic current therapies. At Immune Regulation our aim is to develop novel, safe and effective therapies that reset the immune system, transforming the lives of patients with inflammatory and immunological diseases. Forward-Looking Statements
27.03.2020 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |